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Abstract
Activated platelets have known antimicrobial activity against Staphylococcus aureus. Accelerated clearance of
platelets induced by S. aureus can result in thrombocytopenia and increased mortality in patients. Several
recent studies suggest that P2Y12 inhibition protects platelets from accelerated clearance. We therefore
evaluated the effect of P2Y12 inhibition on clinical outcomes in patients with S. aureus bacteremia across a
large national cohort. Our retrospective cohort (2010-2018) included patients admitted to Veterans Affairs (VA)
hospitals with blood cultures positive for S. aureus and treated with standard of care antibiotics. Employing
propensity score-matched Cox proportional hazards regression models, we compared clinical outcomes in
patients treated with clopidogrel for at least the 30 days prior to admission and continuing for at least five days
after admission to patients without any P2Y12 inhibitor use in the year preceding admission. Mortality was
significantly lower among clopidogrel users than P2Y12 inhibitor non-users (n=147 propensity score-matched
pairs): inpatient mortality hazard ratio (HR) 0.11, 95% confidence interval (CI) 0.01-0.86, and 30-day mortality
HR 0.43, 95% CI 0.19-0.98. There were no differences in 30-day readmission, 30-day S. aureus reinfection,
microbiological clearance, or thrombocytopenia. Clopidogrel use at the time of infection reduced in-hospital
mortality by 89% and 30-day mortality by 57% among a cohort of patients with S. aureus bacteremia. These
results support the need to further study the use of P2Y12 inhibitors as adjunctive therapy in S. aureus
bloodstream infections.

Page 2 of 27

Introduction
Despite appropriate and timely antimicrobial therapy, Staphylococcus aureus bloodstream infections
often result in considerable morbidity and mortality across all age groups (1, 2). S. aureus strains are
heterogenous in their interaction with the host via their broad repertoire of virulence factors. Targeting S.
aureus virulence factors with adjunctive therapies may improve the clinical outcomes of patients with serious S.
aureus infections (3). Recent evidence suggests that platelet adenosine diphosphate P2Y12 inhibitors, such as
clopidogrel, ticagrelor, and prasugrel, may be repurposed as adjunctive therapy to improve outcomes in
patients with S. aureus bacteremia(4, 5).
Ticagrelor is an anti-thrombotic agent used to prevent cardiovascular events in patients with acute
coronary syndrome or a history of myocardial infarction, such as in patients receiving percutaneous coronary
intervention (PCI) (5). Recent evidence suggests ticagrelor may block S. aureus alpha-toxin mediated platelet
cytotoxicity and induced thrombocytopenia, thereby facilitating S. aureus bacteremia clearance by endogenous
platelet-derived antimicrobial peptides and other staphylocidal platelet activities (4, 5). Further, ticagrelor
prevents platelet desialylation driven by S. aureus alpha-toxin (5). Desialylated platelets result in enhanced
platelet clearance via the hepatic Ashwell-Morell receptor (6). As platelets are a key component of innate
immunity in endovascular infections, thrombocytopenia could worsen clinical outcomes in such settings.
Indeed, thrombocytopenia is a strong predictor of mortality in S. aureus bacteremia (7, 8).
In the context of potential benefits of P2Y12 inhibition in S. aureus infection, we retrospectively
compared clinical outcomes of patients with S. aureus bacteremia already on clopidogrel at the time of
infection to those not on P2Y12 inhibitors. We selected clopidogrel as the exposure of interest, as it was the
predominant P2Y12 inhibitor (>96%) utilized among the cohort of patients with S. aureus bacteremia in the VA
Healthcare System during our study period.

Page 3 of 27

Materials and Methods
Data Sources
Clinical data on hospitalizations, medical history, and post-hospitalization outcomes were obtained from
national Veterans Affairs (VA) databases. The study variables were built from demographics data, microbiology
and other laboratory data, diagnosis codes (International Classification of Diseases, Ninth and Tenth
Revisions) from outpatient visits and inpatient stays, and pharmacy data (outpatient and inpatient) (9). This
study was approved by the Institutional Review Board and Research and Development Committee of the VA
Providence Healthcare System (CIRB-2014-047).

Study Design and Population
This retrospective cohort study included patients with S. aureus positive blood cultures collected from
January 1, 2010, to December 1, 2018, during a hospital admission at a VA medical center. The following
inclusion criteria were applied: (1) aged 18 years old or older, (2) hospitalized for more than two days, (3)
survived for more than two days, and (4) cultures collected between one day before admission or one day after
admission. Patients were excluded if they were not on appropriate initial antibiotic therapy within three days of
the culture collection date, defined as intravenous β-lactam therapy (ampicillin-sulbactam, cefazolin, cefepime,
cefotaxime, cefotetan, cefoxitin, ceftaroline, ceftazidime, ceftriaxone, doripenem, ertapenem, imipenem–
cilastatin, meropenem, minocycline, nafcillin, oxacillin, and piperacillin-tazobactam) or ciprofloxacin,
clindamycin, daptomycin, doxycycline, gatifloxacin, gentamicin, levofloxacin, linezolid, moxifloxacin,
tetracycline, tigecycline, sulfamethoxazole-trimethoprim, or vancomycin for methicillin-susceptible S. aureus
(MSSA) and ceftaroline, clindamycin, daptomycin, doxycycline, gentamicin, linezolid, minocycline, tetracycline,
tigecycline, sulfamethoxazole-trimethoprim, or vancomycin for methicillin-resistant S. aureus (MRSA). Patients
were also excluded if the culture was resistant to all initial antibiotic therapies received. In the case of multiple
hospital admissions during the study period, only the first admission was selected for analysis.

Exposure
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To capture patients already on clopidogrel at the time of S. aureus infection and continuing clopidogrel
as antibiotic therapy was initiated, we identified patients on clopidogrel for at least 30 days before admission
with continued use for at least five days after admission. Patients on prasugrel (n=5) and ticagrelor (n=9) were
not included in the study due to these low numbers.
P2Y12 inhibitor non-users included patients without any P2Y12 inhibitor use (clopidogrel, ticlopidine,
ticagrelor, prasugrel, cangrelor) in the year before admission through discharge. Additionally, non-users
included those surviving at least five days to correspond with the treatment group.

Outcomes
Outcomes evaluated included time to in-hospital mortality and mortality inside or outside the hospital
within 30 days of admission. Mortality was defined as death due to any cause. During the admission, we
assessed time to microbiological clearance, defined as a negative follow-up blood culture, among patients with
follow-up blood cultures, and time to thrombocytopenia, defined as a follow-up platelet count <150,000/μL,
among patients with follow-up platelet counts. Moderate thrombocytopenia was defined as a platelet count
<100,000/μL. We also evaluated time to S. aureus reinfection and readmission within 30 days of hospital
discharge.

Covariates
Covariates evaluated included demographics, clinical characteristics, and medical history (Table 1).
Clinical characteristics and medical history consisted of any indications or contraindications for P2Y12 use,
current treatment specialty, source of admission, antibiotic treatment, the timing of culture collection from
admission, concomitant medications with antiplatelet activity, such as aspirin and statins, and adjunctive
therapies that may improve patient outcomes, such as oseltamivir (5), previous healthcare exposures,
antibiotic exposures, and infections, coinfections with other organisms, comorbidities in the prior year and
comorbidity burden (Elixhauser score).

Statistical Analyses
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Differences in demographics, clinical characteristics, and medical history were compared between
clopidogrel users and P2Y12 inhibitor non-users using chi-square or Fisher exact test for categorical variables
and t-test or Wilcoxon rank-sum test for continuous variables. Propensity scores were developed for exposure
to clopidogrel users compared with P2Y12 inhibitors, as a function of all known confounders and potential
confounders associated with exposure and clinical outcomes. (8, 10) Likelihood ratio testing was used to
identify variables independently associated with both exposure and clinical outcomes. Propensity scores were
developed using unconditional logistic regression with manual backward stepwise elimination, and assessed
for the absence of multi-collinearity and goodness of fit. We matched clopidogrel users to P2Y12 inhibitor nonusers on their propensity score using nearest neighbor matching within a caliper of 0.0001. We assessed
absolute standardized differences before and after matching to assess balance of potential confounders.(11)
Common support of the propensity score was assessed visually.(11, 12) Unadjusted and matched hazard
ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard regression
models. Any variable with an absolute standardized difference greater than 0.2 after matching, was assessed
in the Cox model and retained if statistically significant. We conducted stratified analyses by baseline platelet
count and MRSA/MSSA status. SAS software v.9.2 (SAS Institute, Cary, NC) was used for all analyses.
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Results
Our VA-based study included 355 clopidogrel users and 11,144 non-users, all with S. aureus
bacteremia, with mean respective ages of 69 (+/- SD 10) and 66 (+/- SD 13) years, and comprised of >97%
males. Demographics and patient characteristics for the overall cohort and the propensity score-matched
cohort are presented in Table 1. All variables included in the propensity score can be found in the footnote of
Table 2 and Supplemental Table 1. Propensity scores of the clopidogrel users and non-users demonstrated
complete overlap (Supplemental Figure 1: Common support of the propensity score). Patient characteristics
were well balanced in the propensity score-matched cohort (147 matched pairs). Absolute standardized
differences before and after matching can be found in Supplemental Table 1.

Platelet Counts
There were no differences in mean platelet counts between clopidogrel users and P2Y12 inhibitor nonusers at the time of hospital admission in both the overall and propensity score-matched cohorts. The median
platelet count was similar in clopidogrel users (206,000/μL, interquartile range [IQR]149,000-283,000) and
P2Y12 inhibitor non-users (212,000/μL, IQR 146,000-296,000, p=0.42) in the overall cohort. Figure 1 displays
the similar mean daily platelet counts during admission for clopidogrel users and P2Y12 inhibitor non-users in
the overall and propensity score-matched cohorts. Clopidogrel users and P2Y12 inhibitor non-users both
demonstrated a nadir in the first 48 hours after hospitalization, followed by a steady rise peaking at 10-14 days,
and mild decline hitting a plateau at three weeks and beyond in both the overall and propensity score-matched
cohorts.

Clinical Outcomes
Table 2 presents clinical outcomes in clopidogrel users compared with P2Y12 inhibitor non-users. The
inpatient mortality rate was 7.8% in the study population (n=893/11,499). Among the propensity score-matched
cohort, mortality was significantly lower among clopidogrel users: inpatient mortality hazard ratio (HR) 0.11,
95% confidence interval (CI) 0.01-0.86, and 30-day mortality HR 0.43, 95% CI 0.19-0.98. Kaplan-Meier
survival curve of inpatient mortality and 30-day mortality in the propensity score matched cohort are presented
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in Figures 2 and 3. There were no other significant differences in clinical outcomes, including microbiological
clearance (HR 0.87, 95% CI 0.62-1.21) or thrombocytopenia (HR 0.90, 95% CI 0.57-1.40) during the
admission or readmission (HR 0.93, 95% CI 0.54-1.60). The median length of bacteremia among patients with
follow-up cultures was 2 days in both groups.
Clinical outcomes were assessed by baseline platelet counts, stratified by <100,000/μL and
≥100,000/μL. The number of patients with moderate thrombocytopenia (platelet count <100,000/μL)
represented only 10.0% (n=1,153) of clopidogrel users and P2Y12 inhibitor non-users. In the stratified
analyses by baseline platelet count and MSSA/MRSA, no statistically significant differences in any of the
clinical outcomes evaluated were noted between clopidogrel users and P2Y12 inhibitor non-users among the
propensity score-matched cohort (Supplemental Tables 2-4), including 30-day mortality in patients with
baseline platelet count ≥100,000/μL (HR 0.56, 95% 0.25- 1.27), MSSA infection (HR 0.38, 95% 0.10- 1.41),
and MRSA infection (HR 0.20, 95% 0.02- 1.71).
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Discussion
We found that among patients with S. aureus bacteremia in VA medical centers, those already on
P2Y12 inhibitors (specifically clopidogrel as the preferred P2Y12 inhibitor used in the VA) before hospital
admission and continued through the initial 5-day period of antibiotic treatment had an 89% lower risk of
inpatient mortality and 57% lower risk of 30-day mortality than patients who were not exposed to any P2Y12
inhibitors during the admission or the year prior. These findings build further upon data provided by prior
studies that the repurposing of P2Y12 inhibitors in treating S. aureus bacteremia should continue to be studied,
particularly the newer agents (4, 5).
Our results are encouraging, as despite appropriate antibiotic therapy, mortality from S. aureus
bacteremia can still be as high as 10-20% (13). Therefore, there is ample room for improved therapy, including
adjunctive approaches that attenuate S. aureus virulence factor effects on the host and/or enhance innate host
immunity against the pathogen. Our results advance recent findings that the P2Y12 inhibitor ticagrelor may
augment platelet-mediated killing of S. aureus and possibly protect platelets from alpha-toxin mediated injury
and/or accelerated clearance (4, 5). We found positive effects of clopidogrel continuation early in the hospital
course on mortality in patients with S. aureus bacteremia, when the effect of antimicrobial therapy on reducing
inoculum would not yet have taken effect and where alpha-toxin production may be most impactful in driving
the clinical presentation. Indeed, pathogen and infection-specific factors, which we controlled for with
propensity-score matching, weighs much more heavily on early mortality compared to later on in patients with
S. aureus bacteremia (10).
Despite the observed benefit on mortality in S. aureus bacteremia with clopidogrel, some additional
questions were raised by our study. We observed no differences in risk of thrombocytopenia or in mean
platelet counts between clopidogrel users and P2Y12 inhibitor non-users. Given that P2Y12 inhibitors have
been shown to protect platelets from alpha-toxin desialylation and clearance, the benefit of clopidogrel would
perhaps have been anticipated to be driven by reduced thrombocytopenia risk and/or higher platelet counts at
the time of clinical presentation of S. aureus bacteremia in patients taking it (6-8). However, this did not appear
to be the case as both clopidogrel users and P2Y12 inhibitor non-users showed a similar drop in platelet
counts at admission, achieving a nadir around 48 hours and then climbing (Figure 2). Nevertheless, P2Y12
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inhibitors have been shown to directly enhance the platelet-mediated killing of S. aureus in vitro, independent
of platelet count (4, 5). This enhancement of platelet-driven S. aureus killing may play a role in benefiting
treatment at the beginning of hospitalization, where platelet counts were observed to drop approximately 2025% in all groups. It was not immediately clear whether the benefit on clinical outcomes in clopidogrel users
compared with P2Y12 inhibitor non-users seen would persist beyond the hospitalization, as there was no
difference in readmission and reinfection at 30 days between groups. It may be possible that initial protective
effects wane, impacting attributable mortality and other clinical outcomes as a direct cause of S. aureus
bacteremia, which does not continue through to indirect non-attributable causes of death and other outcomes
at later time points (13, 15).
We also did not observe any difference in microbiological clearance between the groups. Limited
previous work has demonstrated that despite ticagrelor having no direct bactericidal activity, the drug has
boosted platelet killing of MSSA at concentrations attainable through standard dosing (4). As such, since in our
study there was no difference in thrombocytopenia or in mean platelet counts between the groups, our results
related to microbiological clearance correspond with the current literature. Additionally, our findings may be
related to the evaluation of chronic clopidogrel use on microbiological clearance, as compared to incident, or
new, use. In a case report of a patient with a complex MSSA endovascular infection and accompanying
thrombocytopenia, the initiation of ticagrelor on day 5 was associated with rapid blood culture clearance the
next day and an increase in platelet count into the low normal range (4). Future work should explore whether
the therapeutic benefit of PGY12 inhibition on clinical outcomes in patients with S. aureus bacteremia is
impacted by the timing of initiation of the PGY12 inhibitor (new versus chronic use).
Identifying adjunctive therapies which target S. aureus virulence factors or enhance innate immunity in
patients with S. aureus bacteremia is important, not just to improve patient outcomes but also to increase the
understanding of the pathophysiology of the disease that may lead to novel future therapeutics. Prior studies
suggest that utilizing P2Y12 inhibitors to enhance the innate immune host defense by boosting plateletmediated S. aureus killing are further supported by these findings (4, 5). However, these findings also suggest
study designs must be carefully planned and thought out because P2Y12 inhibitors may not offer benefit to all
patients with S. aureus bacteremia and, indeed, perhaps in only a small subset of patients. S. aureus
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bacteremia represents a heterogenous group of infections, the final common pathways of which result in the
presence of S. aureus in the bloodstream (16). Some infections are based in the vascular system, while others
are secondary to invasive infections, such as skin, soft tissue, lung, and other sites (16). S. aureus strains
themselves differ widely in their production of virulence factors, including alpha-toxin (5). Additionally, there is a
growing repertoire of P2Y12 inhibitors of varying potency and pharmacokinetic profiles. This study focused on
the older generation P2Y12 inhibitor, clopidogrel, but newer agents such as ticagrelor or cangrelor may offer a
more robust clinical effect. Cangrelor appears particularly entertaining in the acute care setting given its
parenteral administration and shorter half-life, a positive attribute if a hemorrhagic complication should emerge
and therapy needs to be immediately discontinued (17). While we did not assess hemorrhagic complications,
we did not observe a difference in thrombocytopenia between clopidogrel users and non-users. Future
studies should assess hemorrhagic concerns, given the strong possibility of metastatic infection in patients with
S. aureus bacteremia, particularly to the brain. Given the concern of metastatic infection that may be present in
patients with left-sided endocarditis, we would advocate for an initial clinical trial of P2Y12 inhibitors in patients
with right-sided endocarditis, especially with concomitant thrombocytopenia where the host platelet-mediated
innate defense against S. aureus is highly compromised but particularly relevant and would require therapeutic
assistance.
There are some potential downsides to P2Y12 inhibition in the treatment of S. aureus bacteremia.
Although P2Y12 inhibitors protect platelets from alpha-toxin desialylation and clearance, previous work has
demonstrated that cangrelor (a specific P2Y12 antagonist) mitigated platelet staphylocidal response by
blocking platelets from releasing granular-based antimicrobial peptides (platelet microbicidal proteins and
platelet kinocidins).(4, 5, 18) Additionally, alpha-toxin release and lysis of platelets may have a salutary
response against S. aureus by evoking release of platelet antimicrobial peptides.(19)
There are some limitations to our study. The first is that our study cohort included patients with S.
aureus bacteremia who were already on clopidogrel prior to admission, as opposed to patients in a clinical trial
who may be initiated on clopidogrel therapy at the time of S. aureus bacteremia diagnosis. We included
patients already on clopidogrel, as the inclusion of those newly initiated on P2Y12 inhibitors may introduce
selection bias where those started on clopidogrel may have been less sick and/or physicians decided to be
Page 11 of 27

more aggressive with antiplatelet therapy in the setting of the central nervous system and/or cardiac diseases
or procedures, such as endovascular stents. However, our study cohort of current clopidogrel users may be at
different risk for hemorrhagic complications than those newly initiated on clopidogrel in a clinical trial. For
example, the initiation of aspirin treatment was trialed in patients with infective endocarditis to reduce embolic
risk, based on the knowledge that this metric was significantly reduced in patients already on aspirin at the time
of the diagnosis.(20) In clinical trials, the addition of aspirin did not reduce the risk of embolic events but
actually was associated with an increased risk of bleeding.(20) Moreover, our study cohort also required
clopidogrel users to be continued on the drug for at least 5 days after admission, therefore potentially excluding
those who may have been doing poorly and had their chronic medications stopped on admission.
Another major concern is the inability to control for all factors that contribute to confounding between
patients with S. aureus bacteremia receiving clopidogrel versus non-P2Y12 inhibitor users. We used
propensity score matching to mitigate the impact of confounding between the treatment groups. While our
propensity score included observed and known confounders related to clopidogrel use versus non-P2Y12 use,
including demographics, comorbidities, contradictions/indications, concomitant antithrombotic agents, prior
healthcare exposures, and other clinical characteristics, there is the potential for residual confounding due to
other unmeasured factors. For example, severity not captured by intensive care treatment, concomitant
diagnosis codes, and clinical characteristics or easier to clear syndromes, such as peripheral vascular
catheter-associated S. aureus bacteremia, may cause residual confounding. We could not assess why patients
in the comparison group were not on P2Y12 therapy, if indicated, and could also not assess clopidogrel
metabolism. As such, another interpretation could be that among patients who have the same predicted
probability of receiving clopidogrel therapy, actually being on clopidogrel may be protective against mortality, in
patients who can metabolize clopidogrel. Also, while we matched patients on baseline platelet count, we did
not assess mean platelet volume (MPV), which correlates with platelet function and activation. Additionally, we
assessed all cause-mortality and therefore underlying health status or coinfections may have impacted
mortality. However, we did control for underlying conditions and coinfections in the propensity score model.
Due to the retrospective nature of our study, we do not have detailed microbial characterization of the S.
aureus strain, which is a limitation due to the highly heterogeneous nature of S. aureus in terms of virulence
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and toxin production. Additionally, we defined microbiological clearance as a negative follow-up blood culture,
but patients may or may not have had a bacterial clearance of infection at their principal site of infection.
Finally, the VA population consists primarily of older white males; therefore, the generalizability of this study
may be limited.
In summary, this retrospective cohort of VA patients with S. aureus bacteremia demonstrated a
significant reduction in all-cause mortality in patients receiving P2Y12 inhibitors (clopidogrel). These results
build upon prior data that the repurposing of P2Y12 inhibitors warrants further study in prospective clinical trials
in order to validate these agents as viable adjuncts. Such trials may need to focus on subgroup(s) of S. aureus
bacteremia patients where benefits may outweigh risks, such as those with right-sided endocarditis, presence
of thrombocytopenia, or infections by strains with higher alpha-toxin production.
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Tables
Table 1. Baseline demographics and patient characteristics among clopidogrel users compared with P2Y12 inhibitor non-users in the
overall and propensity score matched cohorts
Patient characteristics

Overall clopidogrel

Overall P2Y12

users (n=355)

inhibitor non-users

P-value

Matched clopidogrel

Matched P2Y12

users (n=147)

inhibitor non-users

(n=11,144)

P-value

(n=147)

Age (years), mean (SD)*

69 (10)

66 (13)

<0.0001

70.3 (11.0)

68.3 (11.3)

0.14

Male*

352 (99.2%)

10,861 (97.5%)

0.04

146 (99.3%)

145 (98.6%)

1.0

White*

268 (75.5%)

7,871 (70.6%)

0.05

109 (74.2%)

115 (78.2%)

0.41

Hispanic or Latino*

24 (6.8%)

848 (7.6%)

0.55

11 (7.5%)

14 (9.5%)

0.53

Married*

158 (44.5%)

4,340 (38.9%)

0.03

66 (44.9%)

64 (43.5%)

0.81

2010-2012

102 (28.7%)

4,148 (37.2%)

0.003

47 (32.0%)

42 (28.6%)

0.79

2013-2015

121 (34.1%)

3,526 (31.6%)

43 (29.3%)

47 (32.0%)

2016-2018

132 (37.2%)

3,470 (31.1%)

57 (38.8%)

58 (39.5%)

120 (33.8%)

3,886 (34.9%)

0.68

51 (34.7%)

52 (35.4%)

0.90

142 (40.0%)

4,715 (42.3%)

0.39

50 (34.0%)

58 (39.5%)

0.33

Year of admission*

Methicillin-resistant
Staphylococcus aureus
strain*
Concomitant S. aureus in

Page 17 of 27

other culture sites
Skin and soft tissue*
Urine*

87 (24.5%)

1,910 (17.1%)

0.0003

24 (16.3%)

32 (21.8%)

0.23

Bone joint*

29 (8.2%)

1,504 (13.5%)

0.004

17 (11.6%)

7 (4.8%)

0.03

Other

11 (3.1%)

559 (5.0%)

0.10

<5 (<3.4%)

8 (5.4%)

0.24

11 (3.1%)

590 (5.3%)

0.07

7 (4.8%)

7 (4.8%)

1.0

17 (4.8%)

775 (6.9%)

0.11

<5 (<3.4%)

6 (4.1%)

0.28

77 (21.7%)

2,495 (22.4%)

0.75

25 (17.0%)

29 (19.7%)

0.55

7 (2.0%)

464 (4.2%)

0.04

<5 (<3.4%)

<5 (<3.4%)

1.0

Hospital

167 (47.0%)

5,113 (45.9%)

0.66

72 (49.0%)

65 (44.2%)

0.41

Nursing home

2 (0.6%)

67 (0.6%)

1.0

<5 (<3.4%)

<5 (<3.4%)

0.49

15 (4.2%)

641 (5.8%)

0.2

6 (4.1%)

6 (4.1%)

1..0

Intensive care treatment*

127 (35.8%)

4,031 (36.2%)

0.87

50 (34.0%)

59 (40.1%)

0.28

Surgery during admission*

91 (25.6%)

3,043 (27.3%)

0.48

35 (23.8%)

31 (21.1%)

0.57

Surgery 30 days prior to

22 (6.2%)

724 (6.5%)

0.82

8 (5.4%)

9 (6.1%)

0.80

Respiratory

Concomitant organism in
blood*
Escherichia coli*
Source of admission*
Community

admission*
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Healthcare exposures, past
90 days
Hospitalization
Nursing home

174 (49.0%)

4,231 (38.0%)

<0.0001

59 (40.1%)

58 (39.5%)

0.91

Intensive care

22 (6.2%)

479 (4.3%)

0.08

<5 (<3.4%)

5 (3.4%)

0.45

68 (19.2%)

1,003 (9.0%)

<0.0001

21 (14.3%)

19 (12.9%)

0.73

206 (149-283)

212 (146-296)

0.42

211 (149-289)

202 (146-260)

0.46

29 (7)

28 (7)

0.41

29 (7)

29 (7)

0.35

Acute renal failure*

131 (31.8%)

4,027 (36.1%)

0.77

50 (34.0%)

65 (44.2%)

0.07

Endocarditis

28 (8.7%)

964 (9.4%)

0.69

14 (9.5%)

11 (7.5%)

0.53

Fever*

5 (1.4%)

247 (2.2%)

0.31

<5 (<3.4%)

<5 (<3.4%)

1.0

Pneumonia*

41 (11.6%)

2,019 (18.1%)

0.002

22 (15.0%)

24 (16.3%)

0.75

Respiratory failure*

46 (13.0%)

1,623 (14.6%)

0.40

18 (12.2%)

26 (17.7%)

0.19

Septicemia*

248 (69.9%)

8,010 (71.9%)

0.41

101 (68.7%)

112 (76.2%)

0.15

Shock*

26 (7.3%)

1,021 (9.2%)

0.24

10 (6.8%)

15 (10.2%)

0.29

Baseline platelet count,
median (IQR)*
Body mass index
mean (SD)*
Medical conditions during
admission

P2Y12 inhibitor
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Contraindication*,**

221 (62.3%)

4,418 (39.6%)

<0.0001

77 (52.4%)

71 (48.3%)

0.48

Indication*,***

311 (87.6%)

4,644 (41.7%)

<0.0001

111 (75.5%)

107 (72.8%)

0.59

75 (21.1%)

810 (7.3%)

<0.0001

33 (22.5%)

28 (19.1%)

0.47

76 (21.4%)

257 (2.3%)

<0.0001

9 (6.1%)

15 (10.2%)

0.20

Acute renal failure*

113 (31.8%)

2,802 (25.1%)

0.004

33 (22.5%)

42 (28.6%)

0.23

Alcohol abuse*

26 (7.3%)

1,806 (16.2%)

<0.0001

9 (6.1%)

6 (4.1%)

0.43

Asthma*

21 (5.9%)

475 (4.3%)

0.13

9 (6.1%)

8 (5.4%)

0.80

Atherosclerosis*

271 (76.3%)

2,700 (24.2%)

<0.0001

87 (59.2%)

86 (58.5%)

0.91

Bacterial infection*

94 (26.5%)

2,298 (20.6%)

0.007

34 (23.1%)

29 (19.7%)

0.48

Cancer/ malignancy

125 (35.2%)

4,118 (37.0%)

0.50

60 (40.8%)

55 (37.4%)

0.55

129 (36.3%)

2,787 (25.0%)

<0.0001

45 (30.6%)

52 (35.4%)

0.39

28 (7.9%)

1,176 (10.6%)

0.11

14 (9.5%)

14 (9.5%)

1.0

Medical history, previous
year
Acute cerebrovascular
disease*
Acute myocardial
infarction*

Chronic obstructive
pulmonary disease
Coagulation and
hemorrhagic disorder*
Congestive heart failure*
Diabetes*
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Infective arthritis/

158 (44.5%)

2,183 (19.6%)

<0.0001

48 (32.7%)

52 (35.4%)

0.62

Liver disease

273 (76.9%)

5,968 (53.6%)

<0.0001

103 (70.1%)

102 (69.4%)

0.90

Hypertension*

67 (18.9%)

1,392 (12.5%)

0.0004

22 (15.0%)

19 (12.9%)

0.61

atherosclerosis*

43 (12.1%)

1,672 (15.0%)

0.13

17 (11.6%)

14 (9.5%)

0.57

Pneumonia

323 (91.0%)

7,888 (70.8%)

<0.0001

129 (87.8%)

129 (87.8%)

1.0

Respiratory failure*

163 (45.9%)

1,787 (16.0%)

<0.0001

48 (32.7%)

32 (21.8%)

0.04

Shock*

64 (18.0%)

1,619 (14.5%)

0.07

24 (16.3%)

20 (13.6%)

0.51

Skin and soft tissue

40 (11.3%)

997 (9.0%)

0.13

11 (7.5%)

15 (10.2%)

0.41

infection*

54 (15.2%)

1,696 (15.2%)

0.99

21 (14.3%)

26 (17.7%)

0.43

7 (2.0%)

264 (2.4%)

0.63

<5 (<3.4%)

<5 (<3.4%)

1.0

113 (31.8%)

3,131 (28.1%)

0.12

44 (29.9%)

45 (30.6%)

0.90

Elixhauser, median (IQR)*

6 (4-8)

5 (3-7)

<0.0001

5 (3-7)

5 (4-7)

0.67

Infections, previous year

158 (44.5%)

4,144 (37.2%)

0.005

56 (38.1%)

56 (38.1%)

1.0

101 (28.5%)

2,369 (21.3%)

0.001

34 (23.1%)

35 (23.8%)

0.89

osteomyelitis*

Peripheral visceral

Septicemia

Staphylococcus aureus*
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Medications, previous year
Aspirin
Statin

109 (30.7%)

1,599 (14.4%)

<0.0001

31 (21.1%)

33 (22.5%)

0.78

Oseltamivir

167 (47.0%)

2,258 (20.3%)

<0.0001

52 (35.4%)

59 (40.1%)

0.40

<5 (<1.4%)

39 (0.4%)

0.04

<5 (<3.4%)

<5 (<3.4%)

1.0

Aspirin*

253 (71.3%)

4,481 (40.2%)

<0.0001

85 (57.8%)

90 (61.2%)

0.55

Statin*

307 (86.5%)

4,713 (42.3%)

<0.0001

114 (77.6%)

114 (77.6%)

1.0

Oseltamivir*

9 (2.5%)

178 (1.6%)

0.17

<5 (<3.4%)

9 (6.1%)

0.003

Antibiotic use, previous 30

112 (31.6%)

3,060 (27.5%)

0.09

42 (28.6%)

34 (23.1%)

0.29

27 (7.6%)

610 (5.5%)

0.08

13 (8.8%)

8 (5.4%)

0.26

Ceftaroline

34 (9.6%)

1,264 (11.3%)

0.30

11 (7.5%)

12 (8.2%)

0.83

Clindamycin

10 (2.8%)

389 (3.5%)

0.49

<5 (<3.4%)

9 (6.1%)

0.08

Daptomycin

36 (10.1%)

1,091 (9.8%)

0.83

15 (10.2%)

18 (12.2%)

0.58

Medications during
admission

days
Antibiotics during
admission
Ampicillin-sulbactam*
Carbapenem
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Extended spectrum

33 (9.3%)

1,365 (12.3%)

0.09

11 (7.5%)

24 (16.3%)

0.02

cephalosporins

117 (33.0%)

4,407 (39.6%)

0.01

51 (34.7%)

60 (40.8%)

0.28

Linezolid

89 (25.1%)

3,248 (29.2%)

0.09

41 (27.9%)

47 (32.0%)

0.44

Minocycline

17 (4.8%)

626 (5.6%)

0.50

9 (6.1%)

3 (2.0%)

0.08

Narrow spectrum

16 (4.5%)

710 (6.4%)

0.15

8 (4.4%)

13 (8.8%)

0.26

cephalosporins*

<5 (<1.4%)

73 (0.7%)

1.0

--

--

--

Piperacillin-tazobactam

128 (36.1%)

3,468 (31.1%)

0.05

50 (34.0%)

46 (31.3%)

0.62

197 (55.5%)

6,065 (54.4%)

0.69

74 (50.3%)

81 (55.1%)

0.41

84 (23.7%)

2,737 (24.6%)

0.70

36 (24.5%)

31 (21.1%)

0.49

9 (2.5%)

623 (5.6%)

0.01

6 (4.1%)

<5 (<3.4%)

0.12

22 (6.2%)

473 (4.2%)

0.07

9 (6.1%)

<5 (<3.4%)

0.08

<5 (<1.4%)

58 (0.5%)

1.0

<5 (<3.4%)

<5 (<3.4%)

1.0

340 (95.8%)

10,625 (95.3%)

0.70

139 (94.6%)

142 (96.6%)

0.39

Fluoroquinolones
Gentamicin*

Antistaphylococcal
penicillins*
Sulfamethoxazoletrimethoprim*
Tetracycline
Tigecycline
Vancomycin
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Data are n (%), unless otherwise indicated. SD = standard deviation, IQR = interquartile range. Categorical variables were compared
using chi-square or Fisher’s exact tests where appropriate, means were compared using t-tests, and medians were compared using
non-parametric Wilcoxon tests.
*Variable included in propensity score. Propensity score included all variables with an * in addition to a facility indicator. Full list of
variables included in the propensity score are also presented in the footnote of Table 2 and Supplemental Table 1.
**Any contraindication (coagulation disorders, coronary artery bypass graft and heart vessel operations [procedure], general
hemorrhage, intracranial/cerebrovascular hemorrhage and stroke, gastrointestinal hemorrhage, other hemorrhage).
***Any indications (ischemic heart disease, arteriosclerosis, peripheral vascular disease, arterial thrombus and thrombosis and
atheroembolism, chest pain, other thrombus, percutaneous coronary intervention [procedure], cardiac catheterization [procedure]).
Table 2. Clinical outcomes among clopidogrel users compared with P2Y12 inhibitor non-users in the overall and propensity score
matched cohorts
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Outcomes

No.of events/No.of patients (%)

HR (95% CI)

P2Y12 users

Non-users

18/355 (5.1)

875/11,144 (7.9)

0.77 (0.49-1.23)

4/147 (2.7)

16/147 (10.9)

0.11 (0.01-0.86)

37/355 (10.4)

1,351/11,144 (12.1)

0.85 (0.61-1.17)

13/147 (8.8)

22/147 (15.0)

0.43 (0.19-0.98)

Unadjusted

96/337 (28.5)

2,546/10,269 (24.8)

1.17 (0.96-1.44)

Propensity Matched

34/143 (23.8)

34/131 (26.0)

0.93 (0.54-1.60)

Unadjusted

4/337 (1.2)

173/10,269 (1.7)

0.70 (0.26-1.89)

Propensity Matched

2/143 (1.4)

0/131 (0.0)

--

Unadjusted

338/341 (99.1)

10,353/10,533 (98.3)

1.08 (0.97-1.20)

Propensity Matched

139/141 (98.6)

135/138 (97.8)

0.87 (0.62-1.21)

101/318 (31.8)

3,729/10,157 (36.7)

0.91 (0.74-1.10)

47/144 (32.6)

56/147 (38.1)

0.90 (0.57-1.40)

Sooner outcomes in
P2Y12 non-users

Sooner outcomes
in clopidogrel users

Inpatient mortality
Unadjusted
Propensity Matched
30-day mortality
Unadjusted
Propensity Matched
30-day readmission

30-day S. aureus reinfection

Microbiological clearance*

Thrombocytopenia†
Unadjusted
Propensity Matched

0

1 HR

2

CI=confidence interval; HR=hazard ratio.
Bolded indicates p-value <0.05. The propensity score was dervied from an uncoditional logistic regression model and controlled for
the variables listed below and in Supplemental Table 1. In the matched analysis, Cox proportional hazards models controlled for
current acute renal failure, and history of peripheral and visceral atherosclerosis.
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Variables in the propensity score model: age, antibiotic use 30 days prior to admission, aspirin use during admission, baseline platelet count, body mass index,
concomitant Escherichia coli, concomitant Klebsiella, contraindication (coagulation disorders, coronary artery bypass graft & heart vessel operations [procedure],
general hemorrhage, intracranial/cerebrovascular hemorrhage & stroke, gastrointestinal hemorrhage, other hemorrhage), culture site of Staphylococcus aureus,
current acute renal failure, fever, intensive care admission, pneumonia, respiratory failure, septicemia, Escherichia coli year prior to admission, Elixhauser score,
ethnicity, facility indicator, indication (ischemic heart disease, arteriosclerosis, peripheral vascular disease, arterial thrombus & thrombosis & atheroembolism,
chest pain, other (thrombus), percutaneous coronary intervention [procedure], cardiac catheterization [procedure]), intensive care admission 30 day before
admission, oseltamivir during admission, sex, hospital admission 30 days prior to admission, marital status, methicillin-susceptible/resistant staphylococcus
aureus, nursing home admission 30 days prior to admission, other infection in the previous year, race, staphylococcus aureus infection in the previous year,
source of admission, statins use 30 days prior to admission, statin use during admission, surgery 30 day prior to admission, time to culture collection from
admission, treated with ampicillin-sulbactam, anti-staphylococcal penicillin, gentamicin, narrow spectrum cephalosporin, or sulfamethoxazole/trimethoprim during
admission, treating specialty, year of admission, and history of abdominal hernia, abdominal pain, acute cerebrovascular disease, acute myocardial infarction,
acute renal failure, administrative/social admission, adverse effects of medical drugs, alcohol-related disorders, aortic and peripheral arterial embolism or
thrombosis, aortic/peripheral/and visceral artery aneurysms, appendicitis, aspiration, asthma, bacterial infection, biliary tract disease, cancer, cardiac
dysrhythmias, cerebrovascular disease, chronic obstructive pulmonary disease, chronic ulcer of skin, coagulation and hemorrhagic disorders, complication of
device/implant or graft, conduction disorders, congestive heart failure/non-hypertensive, coronary atherosclerosis and other heart disease, diabetes, diverticulosis
and diverticulitis, epilepsy/convulsions, essential hypertension, fracture of upper limb, gangrene, gastritis and duodenitis, gastrointestinal hemorrhage, heart valve
disorders, hemorrhoids, hepatitis, hypertension with complications and secondary hypertension, joint disorders and dislocations/trauma-related, lymphadenitis,
mental health disorders, multiple sclerosis, nausea and vomiting, nephritis/nephrosis/renal sclerosis, noninfectious gastroenteritis, nonspecific chest pain,
nutritional deficiencies, occlusion or stenosis of precerebral arteries, open wounds of extremities, oral disease (mouth, teeth and jaw), other acquired deformities,
other circulatory disease, other ear and sense organ disorders, other fractures, other injuries and conditions due to external causes, other male genital disorders,
other perinatal conditions, other post-condition care, other skin disorders, other upper respiratory disease, paralysis, Parkinson’s disease, peri- endo-/and
myocarditis/cardiomyopathy, peripheral and visceral atherosclerosis, peritonitis and intestinal abscess, personality disorders, pleurisy/pneumothorax/pulmonary
collapse, rehabilitation care, respiratory failure/insufficiency/arrest, screening and mental health and substance abuse, shock, skin and subcutaneous tissue
infections, skull and face fractures, superficial injury/contusion, transient cerebral ischemia, varicose veins of lower extremity, and vertigo.

*Microbiological clearance was defined as a negative follow-up blood culture. Only includes patients with follow-up blood cultures.

†Thrombocytopenia defined as a follow-up platelet count <150,000/uL. Only includes patients with follow-up platelet counts.
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Figures

Figure 1. Mean platelet counts by day in the overall and propensity score matched cohorts

Footnote: P2Y12 non-users: Day 1, n=9,448, mean=207, standard deviation (sd)=120. Day 7,
n=6,742, mean=275, sd=152. Day 15, n=2,422, mean=296, sd=167.
Clopidogrel users: Day 1, n=286, mean=197, sd=92. Day 7, n=199, mean=287, sd=119. Day
15, n=53, mean=282, sd=124.
Matched P2Y12 non-users: Day 1, n=134, mean=187, sd=96. Day 7, n=91, mean=258, sd=122.
Day 15, n=26, mean=325, sd=140.
Matched clopidogrel users: Day 1, n=129, mean=197, sd=97. Day 7, n=89, mean=288, sd=124.
Day 15, n=22, mean=310, sd=144.

Figure 2. Kaplan-Meier survival curve of inpatient mortality in the propensity score matched
cohort

Figure 3. Kaplan-Meier survival curve of 30-day mortality from admission in the propensity
matched cohort
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